Scopus Case Study: Finding the best scientific minds to partner with
Having access to a robust network of experts provides companies with a leg up in pursuing the most innovative approaches to drug discovery. When exploring uncharted territories such as new therapeutic areas or new molecules, the most competitive companies tap into the best minds in science that will guide them to the right experts to collaborate with and which avenues to pursue. This is where comprehensive access to literature and research trends matters.
“For midsize companies to compete with larger companies that have greater resources, it’s all about agility and creating the most innovative approaches.”
– Calliope Saito, Pharmaceutical R&D Executive
In a recent case study, an R&D executive at a midmarket pharma company describes how her team’s efforts to move compounds successfully through the pre-clinical phase often requires identifying and leveraging external expertise. They use Scopus for quickly finding and assessing potential experts they can connect with to get help in everything from providing cutting-edge research insights to helping with trial design.
Scopus makes it easy to search the literature and discover who is publishing papers in specific fields and topics. This is not only critical for building relationships with subject matter experts to help with one’s own work, but also for keeping tabs on competitors (and, consequently, staying one step ahead of them).
For the R&D executive featured in this case study, the primary and immediate advantages of Scopus are that it boosts productivity and increases the likelihood of success. Whether it’s cutting down on time spent searching or helping researchers get crucial information that prevents them from wasting time down the line, the savings on the clock and additional insight can end up equaling millions of revenue for the company.
“Our compound’s trial was successful, and the FDA granted us a fast-track designation for it. That’s an excellent example of how researching the literature with Scopus really made a difference. Analysts have forecast that this compound will be a multimillion-dollar earner.”
– Calliope Saito, Pharmaceutical R&D Executive